229 related articles for article (PubMed ID: 36032139)
1. Ablation of NLRP3 inflammasome rewires MDSC function and promotes tumor regression.
Papafragkos I; Grigoriou M; Boon L; Kloetgen A; Hatzioannou A; Verginis P
Front Immunol; 2022; 13():889075. PubMed ID: 36032139
[TBL] [Abstract][Full Text] [Related]
2. MDSC-targeting gold nanoparticles enhance PD-1 tumor immunotherapy by inhibiting NLRP3 inflammasomes.
Zhu Y; Chen P; Hu B; Zhong S; Yan K; Wu Y; Li S; Yang Y; Xu Z; Lu Y; Ouyang Y; Bao H; Gu W; Wen L; Zhang Y
Biomaterials; 2024 Jun; 307():122533. PubMed ID: 38493671
[TBL] [Abstract][Full Text] [Related]
3. Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD.
Koehn BH; Saha A; McDonald-Hyman C; Loschi M; Thangavelu G; Ma L; Zaiken M; Dysthe J; Krepps W; Panthera J; Hippen K; Jameson SC; Miller JS; Cooper MA; Farady CJ; Iwawaki T; Ting JP; Serody JS; Murphy WJ; Hill GR; Murray PJ; Bronte V; Munn DH; Zeiser R; Blazar BR
Blood; 2019 Nov; 134(19):1670-1682. PubMed ID: 31533918
[TBL] [Abstract][Full Text] [Related]
4. The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells.
van Deventer HW; Burgents JE; Wu QP; Woodford RM; Brickey WJ; Allen IC; McElvania-Tekippe E; Serody JS; Ting JP
Cancer Res; 2010 Dec; 70(24):10161-9. PubMed ID: 21159638
[TBL] [Abstract][Full Text] [Related]
5. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
Theivanthiran B; Evans KS; DeVito NC; Plebanek M; Sturdivant M; Wachsmuth LP; Salama AK; Kang Y; Hsu D; Balko JM; Johnson DB; Starr M; Nixon AB; Holtzhausen A; Hanks BA
J Clin Invest; 2020 May; 130(5):2570-2586. PubMed ID: 32017708
[TBL] [Abstract][Full Text] [Related]
6. Candida tropicalis induces NLRP3 inflammasome activation via glycogen metabolism-dependent glycolysis and JAK-STAT1 signaling pathway in myeloid-derived suppressor cells to promote colorectal carcinogenesis.
Zhang Z; Chen Y; Yin Y; Chen Y; Chen Q; Bing Z; Zheng Y; Hou Y; Shen S; Chen Y; Wang T
Int Immunopharmacol; 2022 Dec; 113(Pt B):109430. PubMed ID: 36384075
[TBL] [Abstract][Full Text] [Related]
7. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion.
Tengesdal IW; Menon DR; Osborne DG; Neff CP; Powers NE; Gamboni F; Mauro AG; D'Alessandro A; Stefanoni D; Henen MA; Mills TS; De Graaf DM; Azam T; Vogeli B; Palmer BE; Pietras EM; DeGregori J; Tan AC; Joosten LAB; Fujita M; Dinarello CA; Marchetti C
Proc Natl Acad Sci U S A; 2021 Mar; 118(10):. PubMed ID: 33649199
[TBL] [Abstract][Full Text] [Related]
8. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells.
Alissafi T; Hatzioannou A; Mintzas K; Barouni RM; Banos A; Sormendi S; Polyzos A; Xilouri M; Wielockx B; Gogas H; Verginis P
J Clin Invest; 2018 Aug; 128(9):3840-3852. PubMed ID: 29920188
[TBL] [Abstract][Full Text] [Related]
9. Induction of Myeloid-Derived Suppressor Cells in Cryopyrin-Associated Periodic Syndromes.
Ballbach M; Hall T; Brand A; Neri D; Singh A; Schaefer I; Herrmann E; Hansmann S; Handgretinger R; Kuemmerle-Deschner J; Hartl D; Rieber N
J Innate Immun; 2016; 8(5):493-506. PubMed ID: 27351923
[TBL] [Abstract][Full Text] [Related]
10. LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs.
Su MT; Kumata S; Endo S; Okada Y; Takai T
Oncoimmunology; 2022; 11(1):2060907. PubMed ID: 35402083
[TBL] [Abstract][Full Text] [Related]
11. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
12. IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transrepression in cancer.
Yang Q; Li X; Chen H; Cao Y; Xiao Q; He Y; Wei J; Zhou J
Oncogene; 2017 May; 36(21):2969-2980. PubMed ID: 28092673
[TBL] [Abstract][Full Text] [Related]
13. Targeting inflammasome/IL-1 pathways for cancer immunotherapy.
Guo B; Fu S; Zhang J; Liu B; Li Z
Sci Rep; 2016 Oct; 6():36107. PubMed ID: 27786298
[TBL] [Abstract][Full Text] [Related]
14. ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells.
Singh L; Muise ES; Bhattacharya A; Grein J; Javaid S; Stivers P; Zhang J; Qu Y; Joyce-Shaikh B; Loboda A; Zhang C; Meehl M; Chiang DY; Ranganath SH; Rosenzweig M; Brandish PE
Mol Cancer Res; 2021 Apr; 19(4):702-716. PubMed ID: 33372059
[TBL] [Abstract][Full Text] [Related]
15. Baicalein ameliorates pristane-induced lupus nephritis via activating Nrf2/HO-1 in myeloid-derived suppressor cells.
Li D; Shi G; Wang J; Zhang D; Pan Y; Dou H; Hou Y
Arthritis Res Ther; 2019 Apr; 21(1):105. PubMed ID: 31023362
[TBL] [Abstract][Full Text] [Related]
16. Myeloid-derived suppressor cells ameliorate corneal alkali burn through IL-10-dependent anti-inflammatory properties.
Xiao Y; Zhong J; Yang J; Fu Z; Wang B; Peng L; Zuo X; Zhao X; He D; Yuan J
Transl Res; 2023 Dec; 262():25-34. PubMed ID: 37543286
[TBL] [Abstract][Full Text] [Related]
17. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract][Full Text] [Related]
18. Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti-PD-1 immunotherapy.
Theivanthiran B; Yarla N; Haykal T; Nguyen YV; Cao L; Ferreira M; Holtzhausen A; Al-Rohil R; Salama AKS; Beasley GM; Plebanek MP; DeVito NC; Hanks BA
Sci Transl Med; 2022 Nov; 14(672):eabq7019. PubMed ID: 36417489
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of low-dose fludarabine or 5-fluorouracil on the tumor growth and myeloid derived immunosuppression status of tumor-bearing mice.
Abedi-Valugerdi M; Zheng W; Benkessou F; Zhao Y; Hassan M
Int Immunopharmacol; 2017 Jun; 47():173-181. PubMed ID: 28411578
[TBL] [Abstract][Full Text] [Related]
20. Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma.
Chen L; Huang CF; Li YC; Deng WW; Mao L; Wu L; Zhang WF; Zhang L; Sun ZJ
Cell Mol Life Sci; 2018 Jun; 75(11):2045-2058. PubMed ID: 29184980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
